" class="no-js "lang="en-US"> Prasanna Parthasarathy - Medtech Alert
Friday, September 19, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Prasanna Parthasarathy

Prasanna Parthasarathy

About Prasanna Parthasarathy

Proven global business leader with experience across various segments including high tech and medical technologies. Experience in med tech includes HCIT (major focus), medication and supply management, Diagnostic Imaging, Monitoring, Infusion and Ventilation product areas.

Specialties: Healthcare, IT, High tech, Global leadership experience, Growth Strategy, M&A, New market creation, General Management

Related Story

Appointments

 Vytal Announces the Appointment of Prasanna Parthasarathy as Chief Executive Officer | Pharmtech Focus

Vytal Announces the Appointment of Prasanna Parthasarathy as Chief Executive Officer

May 16 2022

Vytal, a pharmacy service and healthcare technology company, today announced the appointment of Prasanna Parthasarathy as chief […]